靶向肿瘤坏死因子 α (TNF-α)（英夫利昔单抗、阿达木单抗、赛妥珠单抗、依那西普）、IL-12 和 IL-23 共有的 p40 亚基（优特克单抗）、IL-23 的 p19 亚基（guselkumab、tildrakizumab、 risankizumab）、IL-17A（苏金单抗、ixekizumab）、IL-17-RA（brodalumab）以及 IL-17A 和 IL-17F（bimekizumab）彻底改变了银屑病的治疗。无论是短期还是长期，与其他口服和注射生物制剂相比，risankizumab 的银屑病面积和严重程度指数 90 得分最高。与 IL-17、IL-12/23 和 TNF-α 抑制剂相比，IL-23 抑制剂的短期和长期不良事件发生率最低，长期风险效益也最有利。版权所有 © 2024 Elsevier Inc 。 版权所有。

Biologic therapies targeting tumor necrosis factor alpha (TNF-α) (infliximab, adalimumab, certolizumab, etanercept), the p40 subunit shared by IL-12 and IL-23 (ustekinumab), the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab), IL-17A (secukinumab, ixekizumab), IL-17-RA (brodalumab) and both IL-17A and IL-17F (bimekizumab) have revolutionized the treatment of psoriasis. In both the short and long term, risankizumab had highest Psoriasis Area and Severity Index 90 scores compared to other oral and injectable biologics. IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-α inhibitors.Copyright © 2024 Elsevier Inc. All rights reserved.